FINWIRES · TerminalLIVE
FINWIRES

$PSNL

7 stories mentioning PSNL

Every FINWIRES story that references PSNL, newest first.

Insider Trading

Personalis Insider Sold Shares Worth $449,292, According to a Recent SEC Filing

Aaron Tachibana, Chief Financial Officer and Chief Operating Officer, on May 29, 2026, sold 38,799 shares in Personalis (PSNL) for $449,292. Following the Form 4 filing with the SEC, Tachibana has control over a total of 198,833 common shares of the company, with 198,833 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1527753/000140178626000004/xslF345X05/form4-05302026_120502.xml

$PSNL
Sectors

Sector Update: Healthcare Stocks Mixed Late Afternoon

Healthcare stocks were mixed late Wednesday afternoon, with the NYSE Healthcare Index up 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.2%.The iShares Biotechnology ETF (IBB) rose 1.9%.In corporate news, Cigna (CI) shares fell 2.5% after Deutsche Bank downgraded the stock to hold from buy and cut its price target to $302 from $303.Medtronic (MDT) said Wednesday it is planning to acquire medical technology firm SPR Therapeutics for an upfront cash payment of about $650 million. Shares were down 0.8%.Personalis (PSNL) shares jumped 12% after the company said its NeXT personal minimal residual disease test has been approved for expanded coverage by the US Centers for Medicare & Medicaid Services' Molecular Diagnostic Services Program.Immunovant (IMVT) shares surged 35% after the firm said its cash and cash equivalents were about $902.1 million as of March 31, providing runway for announced indications through the potential commercial launch of IMVT-1402 in Graves' disease.

$CI$IMVT$MDT$PSNL
Wire

Update: Personalis Shares Rise After NeXT Disease Test Approved for Expanded Coverage by Medicare, Medicaid

(Updates with recent stock movement in the headline and the first paragraph.)Personalis (PSNL) shares rose 9% in Wednesday afternoon trading after the company said its NeXT personal minimal residual disease test has been approved for expanded coverage by the US Centers for Medicare & Medicaid Services' Molecular Diagnostic Services Program.The approval is for monitoring treatment response to neoadjuvant therapy in patients diagnosed with Stage II-III triple-negative breast cancer or HER2-positive breast cancer, it said Wednesday.The coverage decision was backed by clinical evidence from a 227-patient study showing monitoring with NeXT allows accurate tracking of therapy response, outperforming standard clinical metrics, the company said.Price: $7.67, Change: $+0.63, Percent Change: +8.95%

$PSNL
Sectors

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index adding 0.9% and the State Street Healthcare Select Sector SPDR ETF (XLV) increasing 0.7%.The iShares Biotechnology ETF (IBB) rose 0.3%.In corporate news, Corcept Therapeutics (CORT) shares rose past 11% after UBS Securities upgraded the stock to buy from neutral and raised its price target to $72 per share from $44.Ironwood Pharmaceuticals (IRWD) fell 10% after the company said Gregory Martini is resigning from his role as chief financial officer, effective May 15.Personalis (PSNL) shares jumped 6% after the firm said the Molecular Diagnostic Services Program of the Centers for Medicare & Medicaid Services has expanded coverage for its NeXT Personal minimal residual disease test.Assertio (ASRT) shares rose 3.4% after the company said Wednesday it has agreed to be acquired by Zydus Lifesciences subsidiary Zydus Worldwide DMCC in an all-cash tender offer valued at about $166.4 million.

$ASRT$CORT$IRWD$PSNL
Sectors

Sector Update: Healthcare Stocks Advance Wednesday Afternoon

Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 0.8% and the State Street Healthcare Select Sector SPDR ETF (XLV) increasing 0.5%.The iShares Biotechnology ETF (IBB) eased 0.1%.In corporate news, Personalis (PSNL) shares jumped past 7% after the company said the Molecular Diagnostic Services Program of the Centers for Medicare & Medicaid Services expanded coverage for its NeXT Personal minimal residual disease test.Assertio (ASRT) shares rose 3.4% after the company said Wednesday it agreed to be acquired by Zydus Lifesciences subsidiary Zydus Worldwide DMCC in an all-cash tender offer valued at about $166.4 million.UroGen Pharma's (URGN) Zusduri treatment demonstrated a 64.5% 36-month duration of response in a pivotal phase 3 trial in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, the company said Wednesday. Its shares rose 1.9%.

$ASRT$PSNL$URGN
Wire

Sector Update: Healthcare

Healthcare stocks rose Wednesday afternoon with the NYSE Healthcare Index adding 0.5% and the State Street Healthcare Select Sector SPDR ETF (XLV) gaining 0.4%.The iShares Biotechnology ETF (IBB) shed 0.2%.In corporate news, Personalis (PSNL) shares jumped 7.5% after the company said the Molecular Diagnostic Services Program of the Centers for Medicare & Medicaid Services expanded coverage for its NeXT Personal minimal residual disease test.

$PSNL
Sectors

Sector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday

Healthcare stocks were leaning lower pre-bell Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.2% and the iShares Biotechnology ETF (IBB) declining by 0.5%.National Vision Holdings (EYE) stock was down more than 11% after the company reported fiscal Q1 revenue that missed analysts' estimates.Alto Neuroscience (ANRO) shares were down more than 3% after the company posted a wider Q1 net loss.Personalis (PSNL) said the Molecular Diagnostic Services Program of the Centers for Medicare & Medicaid Services has expanded coverage for the firm's NeXT Personal minimal residual disease test. Personalis stock was up more than 14% premarket.

$ANRO$EYE$IBB$PSNL$XLV